A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell Histiocytosis
Clinical trial NCT05828069 · RECRUITING
Trial details
- NCT number
- NCT05828069
- Sponsor
- National Cancer Institute (NCI)
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-03-28
- Primary completion
- 2028-09-30
- Enrollment
- 48
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.